Immuno-oncology

Immunotherapy eBook
#Cancer immunotherapy #eBook #Immuno-oncology #Immunotherapy

Immunotherapy: Opportunities and advances

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. This eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.

#DDW eBooks #Intelligence

T cells attack a cancer cell
#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology #Phase III trial

New podcast: The consistency and value of immunotherapy

This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More

#News

Cancer cells
#Acute inflammatory conditions #Immuno-oncology #Oncodesign Precision Medicine #Oncology #Phase I trial

OPM tests first kinase inhibitor in clinic

Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More

#Cancer Research #News

#Asgard Therapeutics #Cell and gene therapy #Financing #Immuno-oncology #In vivo

€30m raised for first-in-class in vivo cell reprogramming platform

Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming… Read More

#Business & Investment #News

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Events #Immuno-oncology #Oncology

DDW Turning Science into Business Summit: Cancer research

DDW recently hosted an online event, sponsored by Taconic Biosciences, which outlined areas of advancement and opportunity in the cancer research market. Megan Thomas summarises the key points examined by the participating experts. New drug discovery and development concepts The event started with a panel discussion on new drug discovery… Read More

#Cancer Research #Exclusive Content

Bacteria
#Biomica #Cancer research #Immuno-oncology #Microbiome #Oncology #Phase I trial

Results for microbiome-based cancer drug expected H1 2024

Biomica has completed enrolment in its Phase I trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug, BMC128. Initiated in July 2022, the Phase I trial was designed to evaluate BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small… Read More

#Cancer Research #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Colorectal cancer
#Bowel cancer #Cancer research #Cidara #ESMO #Immuno-oncology #Oncology #Preclinical development

Drug-Fc conjugates exhibit robust anti-tumour activity

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More

#Cancer Research #News

Cancer metastasis
#AstraZeneca #Cancer research #Immuno-oncology #Interview #Oncology

Global breakthroughs in cancer drug discovery

Listen to this article on the DDW Podcast: AstraZeneca UK has appointed David Brocklehurst as Head of Oncology in the UK. He spoke with DDW’s Megan Thomas about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. MT: What will you be focusing on in your new role?… Read More

#Cancer Research #Exclusive Content #Opinion

Human antibodies
#Cancer research #Guide #Immuno-oncology #Immunotherapy #Immutep #Oncology

Immunotherapy is here to stay

Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the… Read More

#Cancer Research #Exclusive Content

Genetic engineering concept with medication capsule with human brain diagram at programming language background
#Antibody #Drug discovery #Immuno-oncology #Therapeutic Antibodies #Therapeutics

DDW Summer 2023 issue out now

The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies.  Featuring a Therapeutic Spotlight on Immuno-oncology, the magazine is available to download free here and read for free on the DDW App.  You can also… Read More

#News

Cancer immuno-oncology
#AI / data analytics / healthtech / informatics #Bispecific Antibodies #Bispecific therapeutics #Cambridge Healthtech Institute #Cancer immunotherapy #Events #Immuno-oncology #Next generation sequencing

Immuno-Oncology Summit Europe 2023: Programme highlights 

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes.   Programmes   This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and… Read More

#Cancer Research #Exclusive Content #Opinion

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

New podcast episode: DDW Highlights, 5 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With National Cancer Research Month coming to an end in May and the American Society… Read More

#News

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

This week in drug discovery (29 May – 2 June)

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another… Read More

#News

Monoclonal antibodies
#Aulos Bioscience #Cancer research #Immuno-oncology #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

AI-designed monoclonal antibody ‘redirects’ the immune system

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More

#Cancer Research #Editor's Choice #News